Literature DB >> 6517555

Effect of saturable clearance during high-dose mezlocillin therapy.

G L Drusano, A Forrest, D Fiore, F Auger, E S Caplan.   

Abstract

As mezlocillin has been shown to display nonlinear pharmacokinetics in single-dose evaluations, we evaluated a crossover trial in patients with renal dysfunction the impact on serum clearance of fixed-dose versus fixed-interval administration of identical daily doses of the drug. In four patients with creatinine clearances of 0.00 to 1.78 liters/h per 1.73 m2, equal serum clearances were observed when the calculated daily total dose of mezlocillin was given either as a fixed dose of 5,000 mg at various intervals or every 4 h at various doses. We found that repetitive large daily doses that are equivalent to 30 g/day in patients with normal renal function can be administered to patients with impaired renal function as a reduced dose every 4 h instead of prolonging the dosing interval, as suggested by Mangione et al. (Antimicrob. Agents Chemother. 21:428-435, 1982). The observed serum clearances were equal for the two schedules, probably owing to the degree of continuing saturation of the nonlinear clearance mechanisms of mezlocillin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6517555      PMCID: PMC179995          DOI: 10.1128/AAC.26.5.686

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Mezlocillin pharmacokinetics. Comparison with ampicillin and influence of probenecid.

Authors:  L Verbist; T B Tjandramaga; R Verbesselt; P J De Schepper
Journal:  Arzneimittelforschung       Date:  1979

2.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

3.  Improved procedure for the determination of the ureidopenicillins azlocillin and mezlocillin plasma by high-performance liquid chromatography.

Authors:  R Hildebrandt; U Gundert-Remy
Journal:  J Chromatogr       Date:  1982-03-12

4.  Comparative clinical evaluation of mezlocillin and cefoxitin.

Authors:  J L LeFrock; A Molavi; B Carr; R Schell; B Smith; K Rolston; A Lentnek
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

5.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

7.  Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.

Authors:  N Frimodt-Möller; S Maigaard; R D Toothaker; R W Bundtzen; M V Brodey; W A Craig; P G Welling; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.

Authors:  A Mangione; F D Boudinot; R M Schultz; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

  8 in total
  4 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

3.  Comparative pharmacokinetics of two multiple-dose mezlocillin regimens in normal volunteers.

Authors:  P A Colaizzi; A A Coniglio; W J Poynor; N Vishniavsky; H T Karnes; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  Pharmacokinetics of two multiple-dose mezlocillin regimens.

Authors:  D M Janicke; S W Parker; R F Cafarell; M A Apicella; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.